WallStSmart
NUVB

Nuvation Bio Inc

NYSE: NUVB · HEALTHCARE · BIOTECHNOLOGY

$4.76
-6.77% today

Updated 2026-06-05

Market cap
$1.66B
P/E ratio
P/S ratio
11.64x
EPS (TTM)
$-0.43
Dividend yield
52W range
$2 – $10
Volume
4.0M

Nuvation Bio Inc (NUVB) Financial statements

SEC filings — annual and quarterly data.

Income statement — annual

Item20182019202020212022202320242025
Revenue$0.00$0.00$0.00$0.00$7.87M$62.90M
Revenue growth (YoY)+699.0%
Cost of revenue$103000.00$368000.00$484000.00$222000.00$7.08M$8.44M
Gross profit$-103000.00$-368000.00$-484000.00$-222000.00$795000.00$54.46M
Gross margin10.1%86.6%
R&D$482667.00$25.11M$32.60M$69.04M$87.81M$71.29M$524.19M$115.11M
SG&A$509333.00$6.59M$10.95M$24.28M$31.92M$28.53M$66.73M$151.56M
Operating income$-992000.00$-32.10M$-43.55M$-93.32M$-119.73M$-99.82M$-592.63M$-213.06M
Operating margin-7527.3%-338.7%
EBITDA$-32.09M$-41.56M$-93.13M$-119.53M$-75.58M$-566.91M$-190.94M
EBITDA margin-7200.7%-303.6%
EBIT$-992000.00$-32.10M$-41.66M$-93.32M$-119.73M$-75.80M$-567.60M
Interest expense$0.00$0.00$0.00$644000.00$9.16M$0.00$341000.00$13.68M
Income tax
Effective tax rate0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Net income$-992000.00$-33.55M$-41.66M$-86.85M$-104.20M$-75.80M$-567.94M$-204.63M
Net income growth (YoY)-3282.3%-24.2%-108.5%-20.0%+27.3%-649.2%+64.0%
Profit margin-7213.8%-325.3%

Frequently asked questions

What is Nuvation Bio Inc's revenue?

Nuvation Bio Inc's trailing twelve-month revenue is $143.05M. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.

How profitable is NUVB?

In its most recent fiscal year, NUVB ran a gross margin of 86.58%, an operating margin of -338.72%, and a net margin of -325.31%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.

How much free cash flow does NUVB generate?

NUVB produced $-173.78M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is NUVB's balance sheet healthy?

NUVB holds $164.09M in cash and equivalents against $47.21M in long-term debt, on $305.72M of shareholder equity. Cash on hand exceeds long-term debt, so the balance sheet adds little financial risk to the thesis.